SCHEMBL10244563

SCHEMBL10244563

CNC(=O)NCCCN(C)C

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.50
KDM4E B2RXH2 4/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
PAOX Q6QHF9 1/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
P2RX4 Q99571 1/20 0.41
LMNA P02545 1/20 0.41
EPHX1 P07099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244702 0.94 KEAP1 (0.49) DNM1KDM4EKEAP1NFE2L2PAOX
SCHEMBL36169 0.89 DNM1 (0.55) DNM1KDM4EPAOXHPGDPOLB
Hydrochloric Acid SCHEMBL10730965 0.86 DNM1 (0.53) DNM1KDM4EPAOXHPGDPOLB
SCHEMBL836639 0.86 PRMT3 (0.46) DNM1KEAP1NFE2L2POLBALDH1A1
SCHEMBL24102742 0.84 DNM1 (0.52) DNM1KDM4EPAOXHPGDPOLB
SCHEMBL11149127 0.84 EPHX1 (0.58) DNM1KDM4EPAOXHPGDEPHX1
SCHEMBL19672893 0.83 KDM4E (0.47) DNM1KDM4EPAOXHPGDPOLB
SCHEMBL12707843 0.83 DNM1 (0.50) DNM1KDM4EPAOXHPGDPOLB
SCHEMBL11382117 0.81 KEAP1 (0.55) KDM4EKEAP1NFE2L2MEN1KMT2A
SCHEMBL13466509 0.81 KEAP1 (0.61) KDM4EKEAP1NFE2L2PAOXPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120064482-A Method for simultaneously detecting mussel mucin and recombinant type III collagen 哈尔滨斯达生物科技有限公司 2025-05-30 CN disclosed
US-20210078949-A1 METHODS FOR PREPARATION OF JASMONATE COMPOUNDS VIDAC PHARMA LTD. (IL) 2021-03-18 US disclosed
US-8354418-B2 Thiazolyl-dihydro-quinazolines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-15 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
EP-2114945-B1 PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2010-10-20 EP disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090131424-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-21 US disclosed
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE CYP3A7, UGT2B7, UGT1A7 DNM1 3228/4885KDM4E 4490/4885KEAP1 899/4885
US-20090131424-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE CYP3A7, UGT2B7, UGT1A7 DNM1 3228/4885KDM4E 4490/4885KEAP1 899/4885
US-20210078949-A1 METHODS FOR PREPARATION OF JASMONATE COMPOUNDS SQLE, FDFT1, FDPS DNM1 951/4885KDM4E 2493/4885KEAP1 151/4885
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 DNM1 3156/4885KDM4E 128/4885KEAP1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.